|
286 Companies |
|
367 Products |
|
367 Products |
|
179 Mechanisms of Action |
|
18 Trials |
|
3665 News |
|
| «12...89101112131415161718...7778» |
- Avastin (bevacizumab) / Roche
Trial initiation date, Trial primary completion date: Preliminary Assessment of [18F] Fluciclatide (GE [18F]AH111585) in Glioblastoma Multiforme Treated With Bevacizumab (clinicaltrials.gov) - Sep 22, 2016
P=N/A, N=30, Not yet recruiting, Sponsor: University of Utah
Initiation date: Jun 2016 --> Jan 2017 | Trial primary completion date: Jan 2018 --> Jan 2022
- ICT-121 / EOM Pharma
Enrollment closed: A Study of ICT-121 Dendritic Cell Vaccine in Recurrent Glioblastoma (clinicaltrials.gov) - Sep 22, 2016
P1, N=20, Active, not recruiting, Sponsor: ImmunoCellular Therapeutics, Ltd.
Initiation date: Jun 2016 --> Jan 2017 | Trial primary completion date: Jan 2018 --> Jan 2022 Recruiting --> Active, not recruiting
- | temozolomide / Generic mfg.
Trial completion: Comparison of TransMID vs Standard Treatment of Cancerous Brain Tumors (clinicaltrials.gov) - Sep 21, 2016
P3, N=30, Completed, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting --> Active, not recruiting Recruiting --> Completed
- | everolimus / Generic mfg.
Trial completion, Trial primary completion date: An Open-label, Multi-center, Expanded Access Study of Everolimus in Participants With Advanced Neuroendocrine Tumors (NETs) (Core Study) and an Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced NETs (E1) (clinicaltrials.gov) - Sep 21, 2016
P4, N=15, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: May 2016 --> Aug 2016
- stenoparib (2X-121) / Allarity Therap, Oncoheroes
Trial primary completion date: An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Sep 19, 2016
P1/2, N=41, Active, not recruiting, Sponsor: Eisai Limited
Active, not recruiting --> Completed | Trial primary completion date: May 2016 --> Aug 2016 Trial primary completion date: Nov 2015 --> Jul 2015
- Kimmtrak (tebentafusp-tebn) / Immunocore
Trial primary completion date: IMCgp100 in Advanced Unresectable Melanoma (clinicaltrials.gov) - Sep 19, 2016
P0, N=20, Completed, Sponsor: Abramson Cancer Center of the University of Pennsylvania
Trial primary completion date: Nov 2015 --> Jul 2015 Trial primary completion date: Mar 2012 --> Mar 2013
- Trial completion, Trial primary completion date: Late Effects of Proton Radiation Therapy in Patients With Low-Grade Glioma (clinicaltrials.gov) - Sep 15, 2016
P=N/A, N=20, Completed, Sponsor: Massachusetts General Hospital
Trial primary completion date: Mar 2012 --> Mar 2013 Active, not recruiting --> Completed | Trial primary completion date: Aug 2016 --> Aug 2015
- temozolomide / Generic mfg.
Trial primary completion date: High Dose Interleukin-2 Followed by Intermittent Low Dose Temozolomide in Patients With Melanoma (clinicaltrials.gov) - Sep 15, 2016
P2, N=40, Active, not recruiting, Sponsor: Milton S. Hershey Medical Center
Active, not recruiting --> Completed | Trial primary completion date: Aug 2016 --> Aug 2015 Trial primary completion date: Jun 2016 --> Aug 2017
- carboplatin / Generic mfg.
Trial primary completion date: Safety of BBB Opening With the SonoCloud (clinicaltrials.gov) - Sep 15, 2016
P1/2, N=20, Recruiting, Sponsor: Assistance Publique - H
Trial primary completion date: Jun 2016 --> Aug 2017 Trial primary completion date: Jul 2016 --> Jul 2017
- || agerafenib (RXDX-105) / Roche, Daiichi Sankyo
Trial primary completion date: Study of RXDX-105, Potent RET Inhibitor in Patients With Advanced Lung Cancer and Other Solid Tumors (clinicaltrials.gov) - Sep 15, 2016
P1, N=160, Recruiting, Sponsor: Ignyta, Inc.
Trial primary completion date: Jul 2016 --> Jul 2017 Trial primary completion date: Mar 2017 --> Dec 2017
- Zelboraf (vemurafenib) / Roche
Trial primary completion date: Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma (clinicaltrials.gov) - Sep 15, 2016
P1/2, N=55, Suspended, Sponsor: Massachusetts General Hospital
Trial primary completion date: Mar 2017 --> Dec 2017 Trial primary completion date: Jul 2015 --> Jul 2017
- SL-701 / Menarini
Enrollment closed: Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme (clinicaltrials.gov) - Sep 12, 2016
P1/2, N=74, Active, not recruiting, Sponsor: Stemline Therapeutics, Inc.
Trial primary completion date: Jul 2015 --> Jul 2017 Recruiting --> Active, not recruiting
- || Inlyta (axitinib) / Pfizer
Trial primary completion date, Monotherapy: AxiGII: A Randomized Phase II Clinical Trial on the Efficacy of Axitinib as a Monotherapy or in Combination With Lomustine for the Treatment of Patients With Recurrent Glioblastoma (clinicaltrials.gov) - Sep 9, 2016
P2, N=52, Active, not recruiting, Sponsor: Bart Neyns
Recruiting --> Active, not recruiting Trial primary completion date: May 2015 --> Dec 2016
- Enrollment closed, Trial primary completion date: Dabrafenib and Trametinib for BRAF-inhibitor Pretreated Patients (clinicaltrials.gov) - Sep 9, 2016
P2, N=25, Active, not recruiting, Sponsor: Universitair Ziekenhuis Brussel
Trial primary completion date: May 2015 --> Dec 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2016 --> Dec 2016
- Trial primary completion date: Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors (clinicaltrials.gov) - Sep 8, 2016
P=N/A, N=30, Suspended, Sponsor: O'Dorisio, M S
Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2016 --> Dec 2016 Trial primary completion date: Jul 2016 --> Dec 2018
- temozolomide / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: A Dose Per Fraction Escalation Trial of Hypofractionated IMRT With Temozolomide for Newly Diagnosed Glioblastoma (clinicaltrials.gov) - Sep 7, 2016
P1, N=37, Completed, Sponsor: University of Colorado, Denver
Trial primary completion date: Jul 2016 --> Dec 2018 Active, not recruiting --> Completed | N=27 --> 37 | Trial primary completion date: Mar 2018 --> Jul 2016
- Erivedge (vismodegib) / Roche
Trial primary completion date: Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Patients With Medulloblastomas With an Activation of the Sonic Hedgehog Pathway (clinicaltrials.gov) - Sep 7, 2016
P1/2, N=38, Recruiting, Sponsor: Centre Leon Berard
Active, not recruiting --> Completed | N=27 --> 37 | Trial primary completion date: Mar 2018 --> Jul 2016 Trial primary completion date: Jun 2016 --> Apr 2017
- Enrollment change, Trial termination: Diagnostic Accuracy of Gallium-68-DOTATATE PET/CT Compared to Indium-111-pentetreotide Scintigraphy (SPECT/CT) for Gastroenteropancreatic Neuroendocrine Tumors (clinicaltrials.gov) - Sep 7, 2016
P1/2, N=54, Terminated, Sponsor: University Hospital Inselspital, Berne
Trial primary completion date: Jun 2016 --> Apr 2017 N=133 --> 54 | Recruiting --> Terminated; Superiority of one imaging method
- ||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen
Enrollment closed, Enrollment change: SONNET: Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET (clinicaltrials.gov) - Sep 2, 2016
P2, N=56, Active, not recruiting, Sponsor: Ipsen
N=133 --> 54 | Recruiting --> Terminated; Superiority of one imaging method Recruiting --> Active, not recruiting | N=40 --> 56
- melphalan / Generic mfg.
Trial completion: N99-02: Melphalan and Buthionine Sulfoximine (clinicaltrials.gov) - Aug 30, 2016
P1, N=30, Completed, Sponsor: New Approaches to Neuroblastoma Therapy Consortium
Recruiting --> Active, not recruiting | N=40 --> 56 Active, not recruiting --> Completed
- | Trial completion, Enrollment change: Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma (clinicaltrials.gov) - Aug 26, 2016
P1, N=38, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Terminated --> Completed | N=72 --> 38
- melphalan / Generic mfg.
Enrollment change, Trial termination: Intra-arterial Chemotherapy for the Treatment of Intraocular Retinoblastoma (clinicaltrials.gov) - Aug 24, 2016
P2, N=10, Terminated, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Terminated --> Completed | N=72 --> 38 N=20 --> 10 | Recruiting --> Terminated; IAC is now recognized as part of standard of care treatment options in the US.
- Neupogen (filgrastim) / Kyowa Kirin, Amgen, Azedra (iobenguane I 131) / Lantheus
Trial completion: N2001-02: I-MIBG With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma (clinicaltrials.gov) - Aug 24, 2016
P2, N=50, Completed, Sponsor: Children's Hospital Los Angeles
N=20 --> 10 | Recruiting --> Terminated; IAC is now recognized as part of standard of care treatment options in the US. Active, not recruiting --> Completed
- humanised dinutuximab (Hu14.18K322A) / Essential Pharma
Enrollment closed, Enrollment change: A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma (clinicaltrials.gov) - Aug 19, 2016
P1, N=50, Active, not recruiting, Sponsor: St. Jude Children's Research Hospital
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=75 --> 50
- ViraferonPeg (peginterferon-?-2b) / Merck (MSD), Yervoy (ipilimumab) / BMS
Trial primary completion date: Yervoy With Sylatron Unresectable Stage 3 or 4 Melanoma (clinicaltrials.gov) - Aug 19, 2016
P1, N=31, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Recruiting --> Active, not recruiting | N=75 --> 50 Trial primary completion date: Nov 2016 --> Mar 2017
- Trial completion, Trial primary completion date: PennSCAPE: Melanoma Risk Assessment & Tailored Intervention (clinicaltrials.gov) - Aug 19, 2016
P=N/A, N=323, Completed, Sponsor: University of Pennsylvania
Trial primary completion date: Nov 2016 --> Mar 2017 Active, not recruiting --> Completed | Trial primary completion date: Dec 2011 --> Feb 2016
- Odomzo (sonidegib) / Sun Pharma
Trial primary completion date: A Phase II Study of Oral LDE225 in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB) (clinicaltrials.gov) - Aug 17, 2016
P2, N=22, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed | Trial primary completion date: Dec 2011 --> Feb 2016 Trial primary completion date: Jul 2016 --> Oct 2016
- temozolomide / Generic mfg., cabazitaxel / Generic mfg.
Enrollment closed, Enrollment change, Trial primary completion date: Prospective Phase 2 Trial of Cabazitaxel in Patients With Temozolomide Refractory Glioblastoma Multiforme (clinicaltrials.gov) - Aug 16, 2016
P2, N=24, Active, not recruiting, Sponsor: University of Ulm
Trial primary completion date: Jul 2016 --> Oct 2016 Recruiting --> Active, not recruiting | N=46 --> 24 | Trial primary completion date: Aug 2016 --> Dec 2016
- Trial completion: Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer (clinicaltrials.gov) - Aug 15, 2016
P2, N=7, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Recruiting --> Active, not recruiting | N=46 --> 24 | Trial primary completion date: Aug 2016 --> Dec 2016 Terminated --> Completed
- Trial completion: Cryoablation or External-Beam Radiation Therapy in Treating Patients With Painful Bone Metastases (clinicaltrials.gov) - Aug 15, 2016
P3, N=3, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Terminated --> Completed Terminated --> Completed
- mRNA transfected dendritic cells / Oslo University Hospital
Enrollment change, Trial primary completion date: Trial of Vaccine Therapy With mRNA- Transfected Dendritic Cells in Patients With Advanced Malignant Melanoma (clinicaltrials.gov) - Aug 15, 2016
P1/2, N=31, Completed, Sponsor: Oslo University Hospital
Terminated --> Completed N=22 --> 31 | Trial primary completion date: Aug 2004 --> Feb 2006
- ||| Hiltonol (poly-ICLC) / Oncovir
Trial completion, IO biomarker: MEL58: A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients (clinicaltrials.gov) - Aug 12, 2016
P1, N=53, Completed, Sponsor: Craig L Slingluff, Jr
N=22 --> 31 | Trial primary completion date: Aug 2004 --> Feb 2006 Active, not recruiting --> Completed
- Yervoy (ipilimumab) / BMS
Trial completion, Trial primary completion date: Ipilimumab in Patients With Advanced Melanoma and Spontaneous Preexisting Immune Response to NY-ESO-1 (clinicaltrials.gov) - Aug 12, 2016
P2, N=25, Completed, Sponsor: National Center for Tumor Diseases, Heidelberg
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Jun 2015 --> Aug 2016
- everolimus / Generic mfg.
Trial primary completion date, IO biomarker: A Biological Prospective Study in Patients With Metastatic Pancreatic NETs Treated With Everolimus (clinicaltrials.gov) - Aug 10, 2016
P2, N=47, Recruiting, Sponsor: European Institute of Oncology
Active, not recruiting --> Completed | Trial primary completion date: Jun 2015 --> Aug 2016 Trial primary completion date: Jun 2016 --> Jun 2017
- Trial initiation date, Trial primary completion date: Adoptive Therapy Using Antigen-Specific CD4 T-Cells (clinicaltrials.gov) - Aug 10, 2016
P1, N=12, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Jun 2016 --> Jun 2017 Initiation date: May 2016 --> Dec 2016 | Trial primary completion date: May 2019 --> Dec 2019
- temozolomide / Generic mfg.
Trial primary completion date: Temozolomide in Treating Patients With Newly Diagnosed Anaplastic Oligodendroglioma or Mixed Oligoastrocytoma (clinicaltrials.gov) - Aug 10, 2016
P2, N=60, Active, not recruiting, Sponsor: The Cleveland Clinic
Initiation date: May 2016 --> Dec 2016 | Trial primary completion date: May 2019 --> Dec 2019 Trial primary completion date: Dec 2015 --> Dec 2016
- temozolomide / Generic mfg.
Trial primary completion date: Boron Neutron Capture Therapy, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme (clinicaltrials.gov) - Aug 8, 2016
P2, N=32, Active, not recruiting, Sponsor: Translational Research Informatics Center, Kobe, Hyogo, Japan
Trial primary completion date: Dec 2015 --> Dec 2016 Trial primary completion date: Feb 2016 --> Oct 2016
- | topotecan / Generic mfg.
Trial completion, Trial primary completion date: MIITOP: Iodobenzylguanidine Meta-I131 and Topotecan in Young Patients With Refractory or Relapsed Metastatic Neuroblastoma (clinicaltrials.gov) - Aug 8, 2016
P2, N=30, Completed, Sponsor: Centre Oscar Lambret
Trial primary completion date: Feb 2016 --> Oct 2016 Active, not recruiting --> Completed | Trial primary completion date: Jul 2016 --> Mar 2016
- tasadenoturev (DNX-2401) / DNAtrix
Phase classification: TARGET-I: DNX-2401 With Interferon Gamma (IFN-?) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors (clinicaltrials.gov) - Aug 2, 2016
P1b, N=36, Recruiting, Sponsor: DNAtrix, Inc.
Active, not recruiting --> Completed | Trial primary completion date: Jul 2016 --> Mar 2016 Phase classification: P1 --> P1b
- Avastin (bevacizumab) / Roche
Phase classification: A Study of Bevacizumab Therapy in Patients With Newly Diagnosed High-Grade Gliomas and Diffuse Intrinsic Pontine Gliomas (clinicaltrials.gov) - Aug 1, 2016
P0, N=27, Active, not recruiting, Sponsor: Children's Hospital Medical Center, Cincinnati
Phase classification: P1 --> P1b Phase classification: P=N/A --> P0
- Yervoy (ipilimumab) / BMS
Enrollment change, Trial termination: Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma (clinicaltrials.gov) - Jul 29, 2016
P2, N=12, Terminated, Sponsor: Bristol-Myers Squibb
Phase classification: P=N/A --> P0 N=30 --> 12 | Recruiting --> Terminated; Slow accrual
- Avastin (bevacizumab) / Roche, Torisel (temsirolimus) / Pfizer
Trial completion, Enrollment change, Trial primary completion date: Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma (clinicaltrials.gov) - Jul 29, 2016
P2, N=17, Completed, Sponsor: National Cancer Institute (NCI)
N=30 --> 12 | Recruiting --> Terminated; Slow accrual Active, not recruiting --> Completed | N=23 --> 17 | Trial primary completion date: Dec 2015 --> Jul 2013
- || depatuxizumab mafodotin (ABT-414) / AbbVie
Trial primary completion date: Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme (clinicaltrials.gov) - Jul 28, 2016
P1, N=196, Active, not recruiting, Sponsor: AbbVie
Active, not recruiting --> Completed | N=23 --> 17 | Trial primary completion date: Dec 2015 --> Jul 2013 Trial primary completion date: Jun 2016 --> Jan 2017
- Biomarker, Enrollment closed, Trial primary completion date, Metastases: AMMAM: Circulating Cell-free DNA in Metastatic Melanoma Patient: Mutational Analyses in Consecutive Measurement Before and After Chemotherapy (clinicaltrials.gov) - Jul 28, 2016
P=N/A, N=22, Active, not recruiting, Sponsor: Centre Hospitalier Universitaire de Nice
Trial primary completion date: Jun 2016 --> Jan 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Jul 2014
- Trial completion, Phase classification: Fluorescein for Lymphatic Mapping and Sentinel Lymph Node (SLN) Biopsy in Patients With Stage I and II Malignant Melanoma (clinicaltrials.gov) - Jul 28, 2016
P1/2, N=90, Completed, Sponsor: University of Utah
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Jul 2014 Active, not recruiting --> Completed | Phase classification: P1 --> P1/2
- || ondansetron / Generic mfg., temozolomide / Generic mfg.
Trial primary completion date, CINV: Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide (clinicaltrials.gov) - Jul 26, 2016
P2, N=136, Recruiting, Sponsor: Katy Peters
Active, not recruiting --> Completed | Phase classification: P1 --> P1/2 Trial primary completion date: Jun 2016 --> Jun 2017
- Avastin (bevacizumab) / Roche
Trial primary completion date: Bevacizumab, Temozolomide and Hypofractionated Radiotherapy for Patients With Newly Diagnosed Malignant Glioma (clinicaltrials.gov) - Jul 26, 2016
P2, N=40, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Jun 2016 --> Jun 2017 Trial primary completion date: Oct 2016 --> Oct 2017
- cyclophosphamide / Generic mfg., celecoxib oral / Generic mfg.
Trial termination: Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor Removal (clinicaltrials.gov) - Jul 26, 2016
P1, N=41, Terminated, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Oct 2016 --> Oct 2017 Completed --> Terminated
- SurVaxM (SVN53-67/M57-KLH peptide vaccine) / MimiVax
Trial completion: Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma (clinicaltrials.gov) - Jul 26, 2016
P1, N=9, Completed, Sponsor: Roswell Park Cancer Institute
Completed --> Terminated Active, not recruiting --> Completed
- temozolomide / Generic mfg.
Enrollment closed, Enrollment change: GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma Patients (clinicaltrials.gov) - Jul 26, 2016
P1, N=16, Active, not recruiting, Sponsor: immatics Biotechnologies GmbH
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=20 --> 16